Ionis Pharmaceuticals Inc
IONS81.680USD
-0.130-0.16%
Close 12/05, 16:00（ET）Quotes delayed by 15 min
13.16BMarket Cap
LossP/E TTM
More Details of Ionis Pharmaceuticals Inc Company
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Ionis Pharmaceuticals Inc Info
Ticker SymbolIONS
Company nameIonis Pharmaceuticals Inc
IPO dateMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Number of employees1069
Security typeOrdinary Share
Fiscal year-endMay 17
Address2855 Gazelle Court
CityCARLSBAD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92010
Phone17609319200
Websitehttps://www.ionis.com/
Ticker SymbolIONS
IPO dateMay 17, 1991
CEODr. Brett P. Monia, Ph.D.
Company Executives of Ionis Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
30.57K
-18.30%
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.49K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-0.24%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+2.68%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-5.67%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-14.08%
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
Other
54.02%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.63%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
Capital World Investors
7.85%
BlackRock Institutional Trust Company, N.A.
5.22%
Other
54.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
68.63%
Investment Advisor/Hedge Fund
19.49%
Hedge Fund
13.84%
Research Firm
2.62%
Pension Fund
1.04%
Bank and Trust
0.81%
Individual Investor
0.75%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
23.64M
14.83%
+29.41K
+0.12%
Jun 30, 2025
The Vanguard Group, Inc.
16.68M
10.47%
+329.29K
+2.01%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.05M
10.07%
-126.81K
-0.78%
Jun 30, 2025
Capital World Investors
12.54M
7.87%
+178.19K
+1.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.73M
5.47%
-171.64K
-1.93%
Jun 30, 2025
Wellington Management Company, LLP
6.35M
3.98%
-2.07M
-24.60%
Jun 30, 2025
Bellevue Asset Management AG
7.85M
4.93%
--
--
Jun 30, 2025
State Street Investment Management (US)
4.53M
2.84%
-314.74K
-6.50%
Jun 30, 2025
Deep Track Capital LP
4.89M
3.07%
+327.34K
+7.17%
Jun 30, 2025
Two Sigma Investments, LP
4.46M
2.8%
+678.11K
+17.95%
Jun 30, 2025
View more
Related ETFs
Updated: 23 hours ago
Updated: 23 hours ago
Name
Proportion
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
View more
Invesco Biotechnology & Genome ETF
Proportion5.24%
ARK Genomic Revolution ETF
Proportion4.11%
Virtus LifeSci Biotech Products ETF
Proportion3.34%
Franklin Genomic Advancements ETF
Proportion2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.57%
First Trust Health Care Alphadex Fund
Proportion2.47%
VanEck Morningstar SMID Moat ETF
Proportion2.38%
WisdomTree BioRevolution Fund
Proportion2.28%
State Street SPDR S&P Biotech ETF
Proportion2.28%
Capital Group US Small and Mid Cap ETF
Proportion2.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ionis Pharmaceuticals Inc?
The top five shareholders of Ionis Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC holds 23.64M shares, accounting for 14.83% of the total shares.
The Vanguard Group, Inc. holds 16.68M shares, accounting for 10.47% of the total shares.
T. Rowe Price Investment Management, Inc. holds 16.05M shares, accounting for 10.07% of the total shares.
Capital World Investors holds 12.54M shares, accounting for 7.87% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.73M shares, accounting for 5.47% of the total shares.
Fidelity Management & Research Company LLC holds 23.64M shares, accounting for 14.83% of the total shares.
The Vanguard Group, Inc. holds 16.68M shares, accounting for 10.47% of the total shares.
T. Rowe Price Investment Management, Inc. holds 16.05M shares, accounting for 10.07% of the total shares.
Capital World Investors holds 12.54M shares, accounting for 7.87% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.73M shares, accounting for 5.47% of the total shares.
What are the top three shareholder types of Ionis Pharmaceuticals Inc?
The top three shareholder types of Ionis Pharmaceuticals Inc are:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
How many institutions hold shares of Ionis Pharmaceuticals Inc (IONS)?
As of 2025Q3, 815 institutions hold shares of Ionis Pharmaceuticals Inc, with a combined market value of approximately 172.95M, accounting for 106.78% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.56%.
What is the biggest source of revenue for Ionis Pharmaceuticals Inc?
In FY2020, the R&D revenue under collaborative agreements business generated the highest revenue for Ionis Pharmaceuticals Inc, amounting to 364.56M and accounting for 49.99% of total revenue.
